Guggenheim reaffirms Buy rating and $1,284 price target for Eli Lilly
Guggenheim maintained a Buy rating on Eli Lilly and set a $1,284 price target, implying 11.4% upside versus the Sep 17 close of $1,152.44.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.